Alzamend Neuro Inc Ordinary Shares ALZN 深 沪
等待开盘 11-03 09:30:00 美东时间
2.53
-0.080
-3.07%
华盛通- 最 高2.68
- 今 开2.66
- 成交量 8.69万股
- 最 低 2.45
- 昨 收 2.61
- 总市值 794.39万
- 52周最高 14.31
- 市盈率 静 --
- 换手率 2.77%
- 52周最低 2.06
- 委 比 -33.33%
- 总股本 313.99万
- 历史最高 45292.50
- 量 比 0.41
- 振 幅 8.81%
- 历史最低 2.45
- 每 手 1
- 风险率 3.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alzamend Neuro Issues New Common Stock Shares
Alzamend Neuro ( ($ALZN) ) has provided an announcement. Between October 1 and ...
10-10 05:03
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Alzamend Neuro Boosts Liquidity with Stock Issuance
Alzamend Neuro ( ($ALZN) ) has provided an update. Between September 17 and Sep...
09-26 05:01
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowers the price target from $45 to $42.
09-25 20:02
Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.69) by 85.51 percent. This is a 88.79 percent increase over losses of $(11.42) per share from
09-11 04:41
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $180 to $45.
08-21 17:32
Alzamend Neuro Increases Common Stock Through Conversion
Alzamend Neuro ( ($ALZN) ) has issued an announcement. Between July 23, 2025, a...
08-02 05:06
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro, Inc. will present a study at MHSRS 2025 comparing lithium brain-to-plasma exposure in PTSD patients using AL001 and lithium carbonate. AL001 is a novel lithium-delivery system designed to improve brain targeting and reduce systemic side effects. The study aims to establish optimal dosing for PTSD and other conditions. Alzamend is advancing clinical trials for AL001 to treat Alzheimer's, bipolar disorder, major depressive disorder,...
07-28 12:00
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro reported financial results for the year ended April 30, 2025, highlighting $10.4 million in net cash from financing activities and $4.0 million in stockholder equity, including $3.9 million in cash. In May 2025, the company dosed the first healthy patient in its AL001 "Lithium in Brain" studies at Massachusetts General Hospital. Alzamend also completed its $5 million private placement in June 2025, months ahead of schedule, strengt...
07-23 12:00
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Alzamend Neuro, Inc. has completed a $5 million private placement months ahead of schedule, with proceeds supporting five Phase II clinical trials for AL001 "Lithium in Brain" Studies at Massachusetts General Hospital. The trials target Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD, with the first study expected to report results by year-end. CEO Stephan Jackman expressed gratitude to the investor for accelerating the program...
06-16 12:00
